bluebird bio to Independently Invest in and Pursue a Broad T cell-Based Immuno-oncology Strategy
Investor Conference Call Scheduled for
Under the terms of the amended and restated collaboration agreement:
bluebird bio will receive a
$25 millionpayment to develop the lead anti-BCMA product candidate through a Phase 1 clinical trial and develop next-generation anti-BCMA product candidates.
- bluebird bio will be responsible for the development of all anti-BCMA product candidates through the completion of Phase 1 studies.
Additionally, on a product-by-product basis within the anti-BCMA
Celgenehas an option to develop and commercialize each product candidate worldwide, and bluebird bio has the option to share equally in the development, promotion and profits of each product candidate in the United States. In addition to the payments described above and consistent with the prior agreement, Celgenewould also pay bluebird bio specified development and regulatory milestone payments as well as royalty payments on net sales.
“We have successfully achieved the initial goal of our collaboration
“Our collaboration with bluebird bio has collectively made strong
progress advancing a lead product candidate, targeting BCMA, toward the
clinic in hematologic malignancies. We look forward to continuing to
work with bluebird and build on the recent success to advance the
anti-BCMA program and ultimately, to succeed on the goal of delivering a
high-impact therapeutic in the CAR T arena,” said
A Unique Position in Immuno-oncology
Outside of BCMA, bluebird bio is independently pursuing the development of a broad portfolio of novel immuno-oncology therapeutics. This portfolio will leverage bluebird bio technology, including its lentiviral vector platform, gene editing capabilities and internal gene therapy and immuno-oncology expertise.
“Consistent with the long-term vision for bluebird bio, we are expanding
our immuno-oncology T cell-based efforts in parallel with our late-stage
hematopoietic stem cell-based programs,” said
Currently, bluebird bio has active pre-clinical research programs
targeting multiple different, novel oncology antigens, including BCMA.
These programs include various T cell therapies with significant
academic and industry collaborations. bluebird bio recently announced a
strategic collaboration with
Investor Conference Call and Webcast Information
bluebird bio will host a conference call and webcast at
About bluebird bio, Inc.
With its lentiviral-based gene therapy and gene editing capabilities, bluebird bio has built an integrated product platform with broad potential application to severe genetic diseases and T cell-based immunotherapy. bluebird bio’s clinical programs include Lenti-D™, currently in a Phase 2/3 study, called the Starbeam Study, for the treatment of childhood cerebral adrenoleukodystrophy, and LentiGlobin®, currently in three clinical studies: a global Phase 1/2 study, called the Northstar Study, for the treatment of beta-thalassemia major; a single-center Phase 1/2 study in France (HGB-205) for the treatment of beta-thalassemia major or severe sickle cell disease; and a separate U.S. Phase 1 study for the treatment of sickle cell disease (HGB-206). bluebird bio also has ongoing preclinical CAR T immuno-oncology programs, as well as discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies.
bluebird bio has operations in Cambridge, Massachusetts, Seattle,
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the research, development and advancement of bluebird bio's immuno-oncology product candidates and CAR T research programs. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that bluebird bio's immuno-oncology research programs will be unsuccessful and not identify any viable product candidates or will not be safe or effective in clinical trials, the risk of cessation or delay of any of the planned clinical studies and/or our development of our immuno-oncology product candidates, the risk of a delay in the enrollment of patients in the Company’s clinical studies, the risk that our collaboration with
Availability of other information about bluebird bio
Investors and others should note that we communicate with our investors and the public using our company website (www.bluebirdbio.com), our investor relations website (http://www.bluebirdbio.com/investor-splash.html), including but not limited to investor presentations and FAQs,
Source: bluebird bio, Inc.
bluebird bio, Inc.
Manisha Pai, 617-245-2107
Dan Budwick, 973-271-6085